Four maternal systems are known to pattern the early Drosophila embryo. The key component of the anterior system is the homeodomain protein Bicoid (Bcd). Bcd needs the contribution of another anterior morphogen, Hunchback (Hb), to function properly: Bcd and Hb synergize to organize anterior development. A molecular mechanism for this synergy has been proposed to involve specific interactions of Bcd and Hb with TATA-binding protein-associated factors (TAF II s) that are components of the general transcription machinery. Bcd contains three putative activation domains: a glutamine-rich region, which interacts in vitro with TAF II 110; an alanine-rich domain, which targets TAF II 60; and a Cterminal acidic region, which has an unknown role. We have generated f lies carrying bcd transgenes lacking one or several of these domains to test their function in vivo. Surprisingly, a bcd transgene that lacks all three putative activation domains is able to rescue the bcd E1 null phenotype to viability. Moreover, the development of these embryos is not affected by the presence of dominant negative mutations in TAF II 110 or TAF II 60. This means that the interactions observed in vitro between Bcd and TAF II 60 or TAF II 110 aid transcriptional activation but are dispensable for normal development.
In Drosophila, elaboration of the body plan is directed by maternally encoded information (1) . Four maternal systems of genetic information are involved in setting up the pattern of the embryo. Patterning the anterior region requires input from both the terminal and anterior systems. The terminal system specifies the fate of the poles of the embryo by activating the uniformly distributed receptor tyrosine kinase Torso (Tor) at each end of the early embryo. Loss-of-function mutations in any of the genes implicated in the terminal system give rise to the loss of the anterior portion of the head and of all the structures posterior to and including the eighth abdominal segment (2) (3) (4) (5) (6) .
The anterior region is organized by the bicoid (bcd) gene product, a homeodomain containing transcription factor (Bcd) (7, 8) . bcd mRNA is synthesized during oogenesis and is transported into the egg, where it becomes localized at the anterior tip. This mRNA is translated after the egg is laid, and the protein diffuses away from the anterior tip in the syncytial environment of the early embryo, forming a concentration gradient (9) . Bcd acts as a morphogen: it specifies distinct developmental fates by specifically activating zygotic target genes that respond to a series of Bcd concentration thresholds. In nuclei close to the anterior tip, high concentrations of Bcd activate head gap genes such as orthodenticle (10) . At more posterior positions, lower concentrations of Bcd activate the thoracic gap gene hunchback (hb) (11) (12) (13) . Finally, very low levels of Bcd are able to activate abdominal gap genes like knirps (14) . In addition to its ability to transcriptionally activate a series of target genes, Bcd is also a repressor of posterior development by preventing translation of the ubiquitously distributed maternal caudal mRNA (15) (16) (17) .
bcd mutant females produce embryos that lack all head and thoracic segments and some anterior abdominal segments and show duplication of the telson at the anterior end of the embryo (7) . However, the remaining abdominal segments exhibit a normal anterior-posterior polarity that must be set up by other factors. Bcd is not the only morphogen active in the anterior region of the early fly embryo. A maternal gradient of the zinc-finger transcription factor Hb is also able to pattern the embryo (18) (19) (20) . Therefore, not only does hb represent a zygotic gap gene, which is under the control of Bcd (11) , but it also functions as a maternally provided morphogen. Translation of the homogeneously distributed maternal hb mRNA is blocked in the posterior of the embryo by nanos (21) , thereby generating an anterior-posterior morphogenetic gradient of the Hb protein.
The two morphogens Bcd and Hb work together to organize proper anterior patterning of the fly embryo (22, 23) . In the absence of both maternal and zygotic hb activities, bcd function is strongly affected. An artificial promoter that contains only strong Bcd binding sites is poorly activated in the anterior regions of the embryo. Addition of Hb sites dramatically increases the level of activation and enlarges the domain of reporter gene expression (23) . Bcd and Hb synergize to fulfill their functions. The molecular mechanism underlying the synergy between Bcd and Hb has been elusive. Recently, biochemical studies of the interaction between Bcd, Hb, and the basal transcription factor complex TFIID led to a molecular model that could nicely explain how Bcd and Hb synergize in activating their target genes (24, 25) .
Activation of transcription requires both the contribution of RNA polymerase II and the basal factors TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH (reviewed in ref. 26) . Moreover, the recruitment of the TFIID complex that contains the TATAbinding protein and the TATA-binding protein-associated factors (TAF II s) is necessary for activated transcription. Most Drosophila TAF II s have been cloned, among them TAF II 60 (27) and TAF II 110 (ref. 28 ; reviewed in ref. 29) . It has been proposed that specific TAF II s act as molecular bridges between specific activators and the general transcription machinery (30) . However, different promoters might vary considerably in their requirement for specific TAF II s for transcriptional activation (31) (32) (33) (34) (35) (36) .
Synergistic activation of transcription might result from two activators simultaneously contacting the TFIID complex through different adapter molecules, thus stabilizing the binding of TFIID to the promoter and the association of the remaining basal transcription factors (reviewed in ref. 26 ). Sauer et al. (24, 25) 
MATERIALS AND METHODS
bcd Deletion Constructs. To generate deletion constructs in the bcd coding region, we subcloned the 870-bp BspEI-NsiI fragment from pKSgenomicBCD (37) into pSL1180 (Pharmacia), from which part of the polylinker had been removed by a HpaI and SnaBI digest and religation. The fragment was then taken as a NotI-KpnI fragment and cloned into pBluescriptKS (Stratagene), generating pKSbcdBsp-Nsi, which was used in the following cloning steps. pBcd⌬Q is the result of a HincII and partial BstUI digest and religation, thereby deleting amino acids 247-304. pBcd⌬A and pBcd⌬QA resulted from cloning the 550-bp NciI (Klenow filled-in) to NsiI fragment into a KasI (Klenow filled-in)-and NsiI-or HincII-and NsiI-treated vector backbone, thereby deleting amino acids 331-344 or 247-344, respectively. pBcd⌬AC and pBcd⌬QAC were generated by a KasI (Klenow filled-in) or HincII plus partial ScaI digest and religation, thereby deleting all amino acids C-terminal to amino acid 330 or 246, respectively. pBcd⌬C and pBcd⌬QC resulted from opening the vector pKSbcdBsp-Nsi with a BspEI and partial ScaI digest and cloning into it the BspEI to NciI (Klenow filled-in) fragment from pKSbcdBsp-Nsi (320 bp) or pBcd⌬Q (150 bp), thereby deleting all amino acids C-terminal to amino acid 344. The in-frame fusions were verified by sequencing. The BspEI-NsiI fragments from pKSbcdBsp-Nsi and the deletion constructs were isolated and cloned back into pKSgenomicBCD, thereby replacing the wild-type BspEI-NsiI fragment. The complete genomic coding sequences were taken from these vectors and cloned as BamHI fragments into the BglII site of pCaSpeRBcdBglII. These bcd rescue constructs were then used to generate different transgenic fly lines (37) .
In Vivo Rescue. Two BcdWT, two Bcd⌬A, four Bcd⌬Q, five Bcd⌬C, three Bcd⌬QA, three Bcd⌬QC, two Bcd⌬AC, and six Bcd⌬QAC transgenic lines on the first or second chromosome were crossed into the background to the amorphic bcd E1 allele, and rescue of the bcd phenotype was assessed by cuticular preparations (38) . For each construct, the line with the strongest rescue ability was chosen for further analysis. The presence of the bcd E1 homozygous mutation in the mothers was assessed by the ri and roe markers that flank bcd. The nature of the transgene was verified by genomic PCR amplification by using oligonucleotides flanking the deleted regions in Bcd: 5Ј oligonucleotide, GTCACATGCACATGCAGTAT; and 3Ј oligonucleotide, ACTCCCAAATCTCATCGATC. In Situ Hybridization. Digoxigenin-labeled RNA probes for in situ hybridization were prepared as described (37) . In situ hybridization on whole-mount embryos was performed as described originally (40), with an adaptation (M. Klingler, personal communication). Prehybridization and hybridization were performed at 70°C at pH 5. Embryos were mounted in methyl salicilate͞Canada balsam (1:2) and photographed by using Nomarski optics.
RESULTS

In Vivo Function of the Putative Bcd Activation Domains.
Bcd contains three putative activation domains: a glutaminerich (Q) domain, an alanine-rich (A) domain, and a C-terminal acidic region (C) (Fig. 1 ). The domains of interaction of Bcd with the TAF II s have been mapped in vitro: TAF II 110 binds to the Q domain, whereas TAF II 60 binds to the A domain (25) . The C-terminal region has been shown to be dispensable for bcd function in vivo, but it contributes to increase activation in yeast (41) . Interestingly, the entire activation domain of Bcd can be functionally replaced by a generic activation domain (random acidic amphipathic helix B6) from Escherichia coli (37, (41) (42) (43) .
Because the corecruitment of TAF II s could provide a powerful explanation to the synergistic effect observed between Bcd and Hb during early development, we generated bcd rescue constructs encoding proteins lacking one or several domains of interaction with the TAF II s (Fig. 1 ). These constructs contain DNA encoding the wild-type or deletion variants of the Bcd protein in the context of the genomic bcd locus. We examined their ability to rescue the bcd is a null allele that is truncated after the homeodomain and does not appear to produce a stable protein (12) . Embryos from bcd E1 mothers lack all head and thorax segments and some abdominal segments. Instead, they have a second telson at the anterior end (Fig. 2a) . A construct encoding a wild-type Bcd protein completely rescues the phenotype and behaves like the endogenous gene (Fig. 2b) . Surprisingly, deletion of the A or Q (Bcd⌬A or Bcd⌬Q, respectively) domains or of both domains (Bcd⌬QA) does not abolish rescue activity (Fig. 2, c, d, and f ) . The Bcd⌬C transgene displays a hypomorphic bcd phenotype with only a very partial head but normal thorax and abdominal segments (Fig. 2e ). The Bcd⌬AC construct shows an almost wild-type cuticular phenotype with only small head defects (Fig. 2g) . The lines bearing the Bcd⌬QC deletion (Fig. 2h) exhibit very low rescue, with only the lack of a duplicated telson at the anterior. Although the lines lacking the C domain have a lower potential for rescue than the Bcd⌬Q, Bcd⌬A, and Bcd⌬QA lines, this is likely because of lower levels of expression rather than weaker activator proteins. Consistent with this interpretation, the domain of the hb staining is moved anteriorly in these lines (Fig. 3, d , f, and g). It has been argued that the position of the posterior border of hb indicates the amount of Bcd protein produced, whereas the intensity of staining within this domain reflects the activation potential of the Bcd deletion variant (41) . In fact, two lines expressing a truncation construct lacking the C domain as well as both the Q and A domains (Bcd⌬QAC) have strong rescue activity: these lines exhibit rescue of the thorax and abdominal segments, loss of duplication of the telson at the anterior, and development of head structures (Fig. 2i) . One of these two Bcd⌬QAC lines completely rescues the bcd E1 phenotype (Fig. 2j) . Seventy-five percent of the embryos exhibit wild-type cuticles, and 30% of those are viable. This rescue is probably because of high-level expression of the transgene. Consistent with this, the posterior border of bcd target genes and the position of the cephalic furrow, both strong indicators of the slope of the Bcd protein gradient, are more posterior in this line than in wild-type embryos (Fig. 3h and data not shown) . The ability of Bcd⌬QAC to activate transcription of target genes in vivo is consistent with Schneider cell cotransfection experiments in which the construct exhibits significant transcriptional activity (F.J., R. Sturny, F. Catala, and N. Dostatni, unpublished work). Because the phenotypic rescue of Bcd⌬QAC is not fully Proc. Natl. Acad. Sci. USA 96 (1999) penetrant, the Q, A, and C domains do provide some contribution to the activity of Bcd but are not essential. Bcd-Dependent hb Activation. In a wild-type embryo (Fig.  3a) , hb is transcribed in a broad anterior domain as well as in a more restricted posterior domain. Transcription of the anterior domain of hb is under the control of Bcd and, therefore, is lost in embryos from bcd E1 mutant mothers (13) . Whenever Bcd activity is altered, hb expression is also changed (see above). The posterior border of the anterior hb expression domain is, like the cephalic furrow, positioned in response to the amount of Bcd, whereas the level of expression within this domain reflects the activation potential of the respective Bcd variant (41) . In embryos laid by females homozygous for the bcd E1 mutation and carrying two copies of the transgene Bcd⌬C, Bcd⌬AC, or Bcd⌬QC, the posterior boundary of hb expression is significantly moved toward the anterior (Fig. 3, d,  f, and g ). This is consistent with the fact that these lines only show partial rescue of the bcd E1 phenotype, which appears to be because of a lower level of expression of the transgenes. However, within the hb domain, hb is transcribed at normal levels, which indicates normal activity of these Bcd deletions. The Bcd⌬Q (Fig. 3c) and Bcd⌬QA (Fig. 3e) lines that fully rescue the bcd E1 phenotype show normal amounts of hb expression within a slightly enlarged domain. One of the Bcd⌬A lines (Fig. 3b) exhibits a widely enlarged domain of hb transcription, likely because of the very high level of transgene expression observed by immunostaining (data not shown). Another Bcd⌬A line shows a normal rescue pattern and exhibits a normal position of the cephalic furrow (data not shown). Finally, the domain of expression mediated by the Bcd⌬QAC (Fig. 3h) (24) , and mutations in the respective genes have been isolated in a dominant modifier screen in Drosophila (39) . Mutations in TAF II 60 and TAF II 110 are homozygous embryonic lethal and cell lethal during eye development and oogenesis. However, viable dominant negative alleles of these two genes have allowed Sauer et al. (39) to investigate their effects on transcription. These mutations do not appear to cause a general reduction of transcription, but instead, they affect the expression of only a subset of genes (33, 39 (Fig. 4a) (Fig. 4, b and c) . Rare rescue to wild type can be observed at the same frequency, independently of the presence (Fig. 4d) or absence of dominant negative TAF II mutations (data not shown).
Because the mutations identified in the genes encoding TAF II 110 or TAF II 60 have no direct or specific effect on Bcd activity, even in a highly sensitized situation, this suggests that the synergy between Bcd and Hb is not based on interactions with TAF II s and must, therefore, be mediated by another, still elusive mechanism.
DISCUSSION
Are the TAF II s Dispensable for in Vivo Transcriptional
Activation by Bcd? The mechanisms of transcriptional activation in eukaryotes have been studied extensively, and biochemical studies have established that in vitro mRNA synthesis by RNA polymerase II requires the regulated assembly of multiple protein complexes at promoters (45) . Recent work points to the basal transcription factor complex TFIID as a key (31) (32) (33) (34) (35) (36) . Because TAF II s are supplied maternally and because homozygous TAF II mutants are cell lethal, it is, so far, impossible to create an early embryo that completely lacks TAF II function. Therefore, to test the in vivo relevance of the interaction between the Bcd activation domains and TAF II 60 and TAF II 110, we used alleles of TAF II s that are considered dominant-negative because they can still interact with Bcd but not with TAF II 250 (39) . These mutations have been identified as suppressors of the rough eye phenotype induced by misexpression of an activated form of Ras1. This suppressor effect is likely because of the reduction of the sevenless promotermediated Ras1 expression by the TAF II s mutations (39 , and bcd ) show a complete lack head and thorax (9, 12) , deletions, and fusions of anterior abdominal segments as well as a duplicated telson at the anterior. Generally, these mutations truncate the Bcd protein right after the homeodomain, they are more extensive than Bcd⌬QAC, and they might not produce a stable protein. A less extensive C-terminal deletion of Bcd is encoded by the bcd E5 allele, which belongs to the weakest class of alleles (with bcd 111 and bcd [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] ) (7). bcd E5 truncates the protein at amino acid 264 (12) , which corresponds approximately to the Bcd⌬QAC deletion construct (truncation at amino acid 246). These weak alleles show only slight pattern defects in the anterior head region, lacking the labral derivatives (labrum and dorsal bridge), comparable to the defects produced by the weaker of the Bcd⌬QAC lines. It is likely that a slight increase of the amount of the bcd E5 protein would produce a near normal embryo.
Is the Tight Localization of the bcd mRNA Involved in the Bcd⌬QAC Rescue? The ability of Bcd⌬QAC to fully rescue the bcd E1 phenotype is surprising with respect to previous reports by using injection of mRNA encoding truncation constructs of bcd (41) . mRNA injections of a truncated construct similar to Bcd⌬QAC showed a low rescue potential, even at high concentrations: the construct only suppressed the formation of posterior structures at the anterior. It induced with high frequency thoracic structures and, more rarely, structures of the gnathal region of the head (38) . The difference between the results obtained by mRNA injection or by using transgenic flies could be because of the lack of anterior localization of the injected mRNA. To carry out its morphogenetic function, a gradient of Bcd activity is established by the tight localization of the bcd mRNA to the anterior pole of the egg. This localization depends on the maternal genes exuperentia (exu), swallow (swa), and staufen (stau). Embryos from females homozygous mutant for exu, swa, or stau (2, 55) show head defects similar to those of embryos from females mutant for weak bcd alleles. The labrum is absent and the pharyngeal head skeleton is reduced. Strikingly, the swa, exu, and stau mutants, the weak bcd alleles, and the embryos rescued by injection of the bcd mRNA, are all reminiscent of the torso phenotype: lack of dorsal bridge and labrum. This suggests that that Tor has a enhancing effect on Bcd activity, as has been reported for bcd target gene expression (56) (57) (58) . The tight localization of the bcd mRNA might, thus, be required for Tor to enhance the function of the Bcd protein before it migrates.
Tor-Dependent Phosphorylation of Bcd. It has been shown that Bcd is phosphorylated in response to Tor activity (44) . The strong remaining activity in the Bcd⌬QAC protein that presents such an extensive deletion might be because of the presence of the S/T rich region located between the homeodomain and the Q, A, and C activation domains (Fig. 1) . The S/T-rich sequence is the target of phosphorylations induced by the activity of the terminal Tor pathway: in embryos lacking Tor activity, Bcd phosphorylation is greatly diminished (44) . Activation of the Tor signal transduction pathway leads to activation of a mitogen-activated protein kinase, a nuclear kinase that has been implicated in the phosphorylation of transcription factors. Most mitogen-activated protein phosphorylation sites of Bcd have been mapped in vitro to the S/T rich region. Site-directed mutagenesis indicates that most of the Bcd phosphorylations occur on these sites in vivo (F.J., R. Sturny, F. Catala, and N. Dostatni, unpublished work). The ability of the Tor pathway to create negative charges in this region might allow the generation of an acidic activation domain that compensates for the loss of the other Q, A, and C activation domains.
It has been shown that the Bcd phosphorylations mediate part of the Tor enhancing effect on Bcd activity (F.J., R. Sturny, F. Catala, and N. Dostatni, unpublished work). Hence, the rescue by Bcd⌬QAC could be explained by the fact that the S/T rich region is phosphorylated in vivo by the Tor cascade, thus creating an acidic activation domain on Bcd before it forms its concentration gradient. As long as the homeodomain and the S/T rich region are intact, good rescue is achieved, especially if the transgene is expressed at high levels and mRNA translation occurs in the region of Tor activity.
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